Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) has announced its upcoming participation in two major investor conferences in March 2025. The company will be featured in:

• A fireside chat at the Leerink Global Biopharma Conference on Wednesday, March 12 at 9:20 a.m. ET
• A fireside chat at the UBS Virtual CNS Day on Monday, March 17 at 8:30 a.m. ET

Both events will be accessible through live webcasts on Avadel's Investor Relations website (investors.avadel.com), with recordings remaining available for 90 days after each conference.

News Market Reaction – AVDL

+3.01%

+3.01% Session move

In the trading session that priced this news, AVDL gained 3.01%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

• Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET.
• UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. ET.

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162

FAQ

When is Avadel Pharmaceuticals (AVDL) presenting at the Leerink Global Biopharma Conference in March 2025?

Avadel Pharmaceuticals will present at the Leerink Global Biopharma Conference on Wednesday, March 12, 2025, at 9:20 a.m. ET.

How long will the webcasts of AVDL's March 2025 investor conferences be available?

The webcasts will be available on Avadel's Investor Relations website for 90 days following each conference.

What time is Avadel Pharmaceuticals (AVDL) presenting at the UBS Virtual CNS Day?

Avadel Pharmaceuticals will present at the UBS Virtual CNS Day on Monday, March 17, 2025, at 8:30 a.m. ET.

Where can investors watch Avadel Pharmaceuticals' (AVDL) March 2025 conference presentations?

Investors can watch the presentations through live webcasts available on Avadel's Investor Relations website at investors.avadel.com.